- Home
- HOTH vs MBRX Comparison
HOTH vs MBRX Comparison
Compare HOTH & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- MBRX
- Stock Information
- Founded
- HOTH 2017
- MBRX 2015
- Country
- HOTH United States
- MBRX United States
- Employees
- HOTH N/A
- MBRX N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- MBRX Health Care
- Exchange
- HOTH Nasdaq
- MBRX Nasdaq
- Market Cap
- HOTH 15.6M
- MBRX 17.1M
- IPO Year
- HOTH 2019
- MBRX 2016
- Fundamental
- Price
- HOTH $1.31
- MBRX $0.67
- Analyst Decision
- HOTH Strong Buy
- MBRX Strong Buy
- Analyst Count
- HOTH 3
- MBRX 3
- Target Price
- HOTH $4.00
- MBRX $5.33
- AVG Volume (30 Days)
- HOTH 426.2K
- MBRX 10.5M
- Earning Date
- HOTH 05-12-2025
- MBRX 08-13-2025
- Dividend Yield
- HOTH N/A
- MBRX N/A
- EPS Growth
- HOTH N/A
- MBRX N/A
- EPS
- HOTH N/A
- MBRX N/A
- Revenue
- HOTH N/A
- MBRX N/A
- Revenue This Year
- HOTH N/A
- MBRX N/A
- Revenue Next Year
- HOTH N/A
- MBRX N/A
- P/E Ratio
- HOTH N/A
- MBRX N/A
- Revenue Growth
- HOTH N/A
- MBRX N/A
- 52 Week Low
- HOTH $0.58
- MBRX $0.25
- 52 Week High
- HOTH $3.80
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- HOTH 51.27
- MBRX 52.44
- Support Level
- HOTH $1.21
- MBRX $0.53
- Resistance Level
- HOTH $1.41
- MBRX $0.75
- Average True Range (ATR)
- HOTH 0.10
- MBRX 0.11
- MACD
- HOTH -0.01
- MBRX 0.00
- Stochastic Oscillator
- HOTH 41.30
- MBRX 30.94
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.